India Antibody Drug Conjugates Market Size & Outlook
India antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
India antibody drug conjugates market highlights
- The India antibody drug conjugates market generated a revenue of USD 61.6 million in 2021 and is expected to reach USD 336.7 million by 2030.
- The India market is expected to grow at a CAGR of 20.8% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2021 | USD 61.6 million |
| Market revenue in 2030 | USD 336.7 million |
| Growth rate | 20.8% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Blood Cancer |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, India accounted for 1.1% of the global antibody drug conjugates market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 863.8 million by 2030.
Breast cancer was the largest segment with a revenue share of 59.9% in 2021. Horizon Databook has segmented the India antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
The need for additional treatment options for prevalent forms of cancer, such as breast cancer, led to the introduction of options such Kadycla by Roche around 2015 in the Indian market. Moreover, in 2020, biosimilar drug to Kadcyla was launched in India by Zydus Cadila at a price 80% lower than original price by Roche.
This made the drug more affordable, and therefore, it is expected that the adoption of this product will increase during the forecast period. As per the International Agency for Research on Cancer, with 178,361 new cases of cancer in India in 2020, breast cancer was the most prevalent form of cancer in India, caused mainly due to lack of physical activity, increase in weight, growing use of oral contraceptives, and heightened levels of stress.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
India antibody drug conjugates market size, by application, 2018-2030 (US$M)
India Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
